[Form 4] CUMBERLAND PHARMACEUTICALS INC Insider Trading Activity

Cumberland Pharmaceuticals executive James L. Herman received a grant of 2,500 stock options linked to the company’s common stock.

Rhea-AI Filing Summary

Cumberland Pharmaceuticals executive James L. Herman received a grant of 2,500 stock options linked to the company’s common stock. The options carry an exercise price of 2.80 per share, become exercisable on 2030-03-18, and expire on 2036-03-18.

After this award, Herman holds a total of 21,000 options directly. This is a routine compensation-related grant rather than an open-market purchase or sale, so it does not reflect new trading activity in the company’s stock.

Insider Trade Summary

Grant/Award: 2,500 shares

Grant/Award 1 txn

Insider Herman James L

Role VP and Chief Compliance Office

Type	Security	Shares	Price	Value
Grant/Award	Options (right to buy)	2,500	$2.80	$7K

Holdings After Transaction: Options (right to buy) — 21,000 contracts (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CPIX report for James L. Herman?

Cumberland Pharmaceuticals reported that executive James L. Herman received 2,500 stock options as a compensation grant. These options give him the right to acquire common shares at a fixed price in the future, rather than reflecting an open-market stock purchase or sale.

What are the key terms of James L. Herman’s new stock options at CPIX?

Herman’s grant covers 2,500 options on Cumberland Pharmaceuticals common stock with an exercise price of 2.80 per share. The options become exercisable on 2030-03-18 and expire on 2036-03-18, defining the window during which he can convert them into shares.

How many derivative securities does James L. Herman hold after this CPIX Form 4?

Following the grant, Herman directly holds 21,000 stock options in total. This figure reflects his cumulative derivative position after the 2,500-option award, giving him potential future rights to acquire additional Cumberland Pharmaceuticals common shares if he exercises the options.

Does the CPIX Form 4 show James L. Herman buying or selling stock in the market?

The Form 4 shows a grant of stock options, not an open-market trade. The transaction is coded as an award (code A), meaning Herman acquired derivative rights as part of compensation, rather than buying or selling existing Cumberland Pharmaceuticals shares on the open market.

What role does James L. Herman hold at Cumberland Pharmaceuticals (CPIX)?

James L. Herman serves as an officer of Cumberland Pharmaceuticals, holding the title of Vice President and Chief Compliance Office. The reported option grant reflects part of his compensation package tied to company performance through potential future equity ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/20/2026 - 05:20 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Herman James L

(Last) (First) (Middle)

1600 WEST END AVENUE, SUITE 1300

(Street)

NASHVILLE TENNESSEE 37203

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CUMBERLAND PHARMACEUTICALS INC [ CPIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	VP and Chief Compliance Office

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (right to buy)	$2.8	03/18/2026		A		2,500		03/18/2030	03/18/2036	Common Stock	2,500	$2.8	21,000	D

Explanation of Responses:

Remarks:

	James L. Herman by /s/ John Hamm as attorney-in-fact	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)